Katherine Eban’s latest book, “Bottle of Lies,” has cantered a very intense spotlight on the largely ignored transgressions of the Indian generic pharmaceutical business within the processes they comply with — or all too usually don’t observe — to make high-quality products. This business, which has not often subjected to such rigorous journalistic scrutiny, has lashed again at Eban, engaging her integrity and her work.
The newest salvo comes from Kiran Mazumdar Shaw, who calls Eban’s exposé anecdotal, biased, unfair, and unbalanced, and accuses the author of enjoying as much as the poor perceptions of the Indian pharmaceutical business and the nation. Shaw did this in a softball interview she gave to an Indian publication in which she is an investor.
Shaw, who owns Biocon Ltd, a pharmaceutical company that has been cited multiple times by the United States Meals and Drug Administration over the previous few years for its failure to adjust to Current Good Manufacturing Practices, is among the most notable names within the Indian pharmaceutical trade.
Like many of Eban’s critics, Shaw has tried to want away the concerns raised in “Bottle of Lies” by claiming that the Ranbaxy case on the coronary heart of the e-book (I used to be the whistle-blower who introduced it to gentle) was a one-off incident that occurred 15 years in the past, and so can’t be used to color the whole trade-in poor mild — particularly, as Shaw factors out, when Indian business has finished its share of exceptional deeds by producing massive volumes of affordable medicines for the world.
Things usually are not getting higher, and a part of the reason being as a result of the generic drug business is just too highly effective and influential in India.
If People predict India, which supplies a significant share of the completed drug provide within the U.S., to get its act collectively to enhance the standard of the medicines it makes, I am afraid they are going to be ready a very long time for that to occur. The one resolution is for American lawmakers to enact new laws focused on holding those that deliberately put the public health in danger to account.